89 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
of 2023, resulting in the remaining deferred income for the collaboration being recognized as revenue in March 2023.
Research and development (R&D) expenses … : R&D expenses for the three months ended March 31, 2024, were $35.2 million compared to $25.5 million for the same period in 2023. R&D expenses
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
received R&D tax credits from the UK government in January 2024 of $30.8m
Financial Results for the three months and year ended December 31, 2023
Cash … income for the collaboration being recognized as revenue in March 2023.
Research and development (R&D) expenses: R&D expenses for the three months
8-K
EX-99.1
fswfwpkd
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K/A
EX-99.3
9wvq5di9v6vqxzl
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
fdxianpm veub
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
f5tfkd
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
gfyqn aslrebwivhyb7k
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
oz68bjyn5uod
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
j6u5nbu7vb5
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
u9zmk
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
aapfmz
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am